JPWO2019241442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019241442A5 JPWO2019241442A5 JP2020569024A JP2020569024A JPWO2019241442A5 JP WO2019241442 A5 JPWO2019241442 A5 JP WO2019241442A5 JP 2020569024 A JP2020569024 A JP 2020569024A JP 2020569024 A JP2020569024 A JP 2020569024A JP WO2019241442 A5 JPWO2019241442 A5 JP WO2019241442A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- item
- dose
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 62
- 201000003895 major depressive disease Diseases 0.000 claims description 29
- 239000002775 capsule Substances 0.000 claims description 10
- 206010012378 Depression Diseases 0.000 claims description 9
- 230000003920 cognitive function Effects 0.000 claims description 8
- 201000009916 postpartum depression Diseases 0.000 claims description 7
- 206010054089 Depressive symptom Diseases 0.000 claims description 6
- 206010004939 Bipolar I disease Diseases 0.000 claims description 5
- 206010004938 Bipolar disease Diseases 0.000 claims description 5
- 206010057668 Cognitive disease Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 22
- 150000003839 salts Chemical class 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023205211A JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684155P | 2018-06-12 | 2018-06-12 | |
| US62/684,155 | 2018-06-12 | ||
| US201962789329P | 2019-01-07 | 2019-01-07 | |
| US62/789,329 | 2019-01-07 | ||
| US201962841645P | 2019-05-01 | 2019-05-01 | |
| US62/841,645 | 2019-05-01 | ||
| PCT/US2019/036848 WO2019241442A1 (en) | 2018-06-12 | 2019-06-12 | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023205211A Division JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527092A JP2021527092A (ja) | 2021-10-11 |
| JPWO2019241442A5 true JPWO2019241442A5 (pt) | 2022-06-16 |
Family
ID=67211854
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020569024A Pending JP2021527092A (ja) | 2018-06-12 | 2019-06-12 | １９−ノルｃ３，３−二置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法 |
| JP2023205211A Pending JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023205211A Pending JP2024028849A (ja) | 2018-06-12 | 2023-12-05 | １９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイドおよびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20210338692A1 (pt) |
| EP (1) | EP3806863A1 (pt) |
| JP (2) | JP2021527092A (pt) |
| KR (1) | KR20210021005A (pt) |
| CN (2) | CN112533611A (pt) |
| AU (1) | AU2019287491A1 (pt) |
| CA (1) | CA3103421A1 (pt) |
| IL (1) | IL279315A (pt) |
| MA (1) | MA52894A (pt) |
| MX (1) | MX2020013557A (pt) |
| SG (1) | SG11202012344RA (pt) |
| TW (1) | TW202005653A (pt) |
| WO (1) | WO2019241442A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112472814A (zh) | 2012-01-23 | 2021-03-12 | 萨奇治疗股份有限公司 | 神经活性类固醇制剂和治疗中枢神经系统障碍的方法 |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10774108B2 (en) | 2014-11-27 | 2020-09-15 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| AU2017315682B2 (en) | 2016-08-23 | 2021-11-11 | Sage Therapeutics, Inc. | A crystalline 19-nor C3, 3-disubstituted C21-n-pyrazolyl steroid |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP4069250A1 (en) * | 2019-12-05 | 2022-10-12 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| CN115551514A (zh) | 2020-03-25 | 2022-12-30 | 萨奇治疗股份有限公司 | 用于治疗呼吸系统病症的药物的用途 |
| US20230285417A1 (en) * | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2022197901A1 (en) * | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder |
| IL307991A (en) * | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression |
| WO2022232494A1 (en) * | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| TW202341995A (zh) * | 2022-02-16 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療cns相關病症之神經活性類固醇 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9512165B2 (en) * | 2013-04-17 | 2016-12-06 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof |
| JOP20200195A1 (ar) * | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3206493B1 (en) * | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3158448A1 (en) * | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| AU2017315682B2 (en) * | 2016-08-23 | 2021-11-11 | Sage Therapeutics, Inc. | A crystalline 19-nor C3, 3-disubstituted C21-n-pyrazolyl steroid |
| WO2019051264A1 (en) * | 2017-09-07 | 2019-03-14 | Sage Therapeutics, Inc. | NEUROACTIVE STEROIDS AND METHODS OF USE |
-
2019
- 2019-06-12 JP JP2020569024A patent/JP2021527092A/ja active Pending
- 2019-06-12 SG SG11202012344RA patent/SG11202012344RA/en unknown
- 2019-06-12 AU AU2019287491A patent/AU2019287491A1/en active Pending
- 2019-06-12 MA MA052894A patent/MA52894A/fr unknown
- 2019-06-12 TW TW108120367A patent/TW202005653A/zh unknown
- 2019-06-12 MX MX2020013557A patent/MX2020013557A/es unknown
- 2019-06-12 CN CN201980051843.5A patent/CN112533611A/zh active Pending
- 2019-06-12 CA CA3103421A patent/CA3103421A1/en active Pending
- 2019-06-12 EP EP19737327.7A patent/EP3806863A1/en active Pending
- 2019-06-12 WO PCT/US2019/036848 patent/WO2019241442A1/en unknown
- 2019-06-12 KR KR1020217000726A patent/KR20210021005A/ko unknown
- 2019-06-12 US US17/251,475 patent/US20210338692A1/en active Pending
- 2019-06-12 CN CN202410051762.8A patent/CN117959309A/zh active Pending
- 2019-12-05 US US16/704,800 patent/US20200113917A1/en not_active Abandoned
-
2020
- 2020-12-09 IL IL279315A patent/IL279315A/en unknown
-
2022
- 2022-06-17 US US17/843,031 patent/US20220323462A1/en active Pending
-
2023
- 2023-12-05 JP JP2023205211A patent/JP2024028849A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018507243A5 (pt) | ||
| JPWO2019241442A5 (pt) | ||
| JP2021152060A (ja) | アカンプロセートおよびｄ−サイクロセリンを使用する組み合わせ療法 | |
| JP2020534270A5 (pt) | ||
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2019508476A5 (pt) | ||
| JP2016507500A5 (pt) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2016505050A5 (pt) | ||
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| EP1383495A1 (en) | Duloxetine for treatment of hot flashes | |
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2023011549A5 (pt) | ||
| KR102615988B1 (ko) | 항-n-메틸-d-아스파르테이트 수용체(anti-n-methyl-d-aspartate receptor) 뇌염 예방 또는 치료에 사용하기 위한 벤조산 또는 이의 염 및 유도체 | |
| TW201244732A (en) | Ezatiostat for treating multiple myeloma | |
| RU2721409C1 (ru) | Фармацевтические комбинации ингибитора гистондеацетилаз и ингибитора протеасом или иммуномодулирующего лекарственного средства для лечения рака крови | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| AU2011202639A1 (en) | Compositions and methods for treating myelodysplastic syndrome | |
| Oettmeier et al. | The procaine-base-infusion: 20 years of experience of an alternative use with several therapeutical effects | |
| RU2020143245A (ru) | 19-nor с3,3-замещенный с21-n-пиразолилстероид и способы его применения | |
| JPWO2020023324A5 (pt) | ||
| JPS5938204B2 (ja) | 再生不良性貧血治療剤 | |
| RU2002115814A (ru) | Лечение системной красной волчанки с помощью дегидроэпиандростерона |